News
-
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol Up To 81 Percent In Phase 1b Study
3/26/2012
Amgen (NASDAQ: AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins.
-
ERT And UCLA Initiate Innovative Pilot Program For Chronically Ill Patients
2/9/2012
ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
-
PAREXEL And ASAN Medical Center Establish Alliance To Accelerate Korea-Based Drug Development And Commercialization Programs
2/3/2012
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has entered into an agreement with ASAN Medical Center (AMC), based in Seoul, Korea.
-
CROS NT Announces Further Expansion Into The UK Market
1/11/2012
CROS NT is starting the new year by announcing its expansion into the United Kingdom.
-
Halo Therapeutics' HT-100 Receives FDA's Orphan Designation For Duchenne Muscular Dystrophy
1/5/2012
Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, today announced that the United States Food and Drug Administration (FDA) granted orphan drug designation for HT-100 for treatment of Duchenne muscular dystrophy (DMD).
-
Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress
10/28/2011
Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
-
Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial
10/27/2011
DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
-
Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/27/2011
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
-
New Clinical Treatment Guideline Outlines Recommendations To Reduce Blood Clots After Hip And Knee Replacement
10/12/2011
An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year.
-
Harvard Apparatus Capnograph For Small Rodents & Respiratory Mechanics
10/12/2011
Harvard Apparatus-Hugo Sachs Electronik is proud to introduce the Type 340 Capnograph for small rodents. This extremely low dead space Capnograph makes it suitable for mice as well as other small rodents.
This website uses cookies to ensure you get the best experience on our website. Learn more